Mark Smits

Mark Smits

Guest Researcher


Publication year:
  1. 2024
  2. Published
  3. Published

    Indole-3-carboxyaldehyde does not reverse the intestinal effects of fiber-free diet in mice

    Smits, Mark, Dreyer, S. I. L., Dal, Jenna Elizabeth Hunt, Drzazga, Anna Katarzyna, Modvig, Ida Marie, Holst, Jens Juul & Kissow, Hannelouise, 2024, In: Frontiers in Endocrinology. 15, 1362711.

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Published

    Indole-3-carboxyaldehyde does not reverse the intestinal effects of fiber-free diet in mice

    Smits, Mark, Dreyer, S. I. L., Hunt, J. E., Drzazga, Anna Katarzyna, Modvig, Ida Marie, Holst, Jens Juul & Kissow, Hannelouise, 2024, In: Frontiers in Endocrinology. 15, p. 1362711

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. 2023
  6. Published

    Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384–390

    Smits, Mark & van Raalte, D. H., 2023, In: Diabetes Care. 46, 5, 1 p., e120.

    Research output: Contribution to journalComment/debateResearch

  7. Published

    Endogenous glucagon-like peptide (GLP)-1 as alternative for GLP-1 receptor agonists: Could this work and how?

    Smits, Mark & Holst, Jens Juul, 2023, In: Diabetes/Metabolism Research and Reviews. 39, 8, 17 p., e3699.

    Research output: Contribution to journalReviewResearchpeer-review

  8. Published

    Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial

    Scholtes, R. A., Mosterd, C. M., Hesp, A. C., Smits, Mark, Heerspink, H. J. L. & van Raalte, D. H., 2023, In: Diabetes, Obesity and Metabolism. 25, 1, p. 198-207

    Research output: Contribution to journalJournal articleResearchpeer-review

ID: 300124892